Singapore’s IVF Funding Review Puts Public-Private Price Gap in Focus

Singapore’s review of fertility support has put a price difference at the centre of its in-vitro fertilisation (IVF) market: patients can receive government co-funding at public hospitals, while those choosing private clinics cannot. Health Minister Ong Ye Kung told Parliament in 2026 that financial support for assisted conception was among the policies under review, according to The Business Times. No extension of co-funding to private providers has been announced.

The distinction matters for a treatment that The Business Times said costs about S$15,000 to S$18,000 (US$11,500 to US$13,800) per cycle at a public clinic, compared with roughly S$20,000 to S$25,000 (US$15,400 to US$19,200) at a private facility. IVF involves fertilising eggs with sperm in a laboratory before an embryo is transferred to the womb. Patients may need more than one cycle.

Singapore’s Ministry of Health provides co-funding of up to 75% for eligible assisted conception procedures at public hospitals, The Business Times reported. Patients at both public and private hospitals can also use MediSave, the country’s medical savings scheme, subject to a S$15,000 (US$11,500) lifetime withdrawal limit for assisted conception. The ministry told the newspaper that it provided more than S$20 million (US$15.4 million) annually in co-funding from 2023 to 2025, mainly for IVF.

Demand has grown. Ministry figures reported by both The Business Times and The Straits Times show that assisted reproductive treatment cycles rose from about 5,800 in 2013 to 10,500 in 2022. The Straits Times also reported a planned expansion of capacity across Singapore’s three public hospitals of about 20% once their upgrades are completed.

What a funding change could—and could not—do

Private providers argue that the present funding rules influence where patients seek care. Choy Shook Yee, chief commercial officer of Foundation Healthcare, told The Business Times that competing without the same co-funding available at public hospitals creates a different cost proposition for private clinics. Thomson Medical acting chief executive Cassandra Loh said an extension of co-funding would most immediately narrow the price gap, but cautioned that any effect on private treatment volumes would depend on eligibility rules, funding limits and which procedures qualified.

“Singapore’s low TFR ultimately arises from social root causes, and initiatives through public health or technological solutions can only do so much.”Tan Poh Lin, senior research fellow, Institute of Policy Studies

Those details remain open. Institute of Policy Studies senior research fellow Tan Poh Lin suggested that possible changes could include higher co-funding, larger MediSave withdrawal limits or more funded treatment cycles, according to The Business Times. These were her suggestions, rather than announced government measures. A government workgroup reviewing marriage and parenthood policies is expected to issue recommendations in early 2027, the newspaper reported.

Also, affordability is only one part of access. Fertility Support SG released workplace guidance for employees undergoing treatments such as IVF and intrauterine insemination, according to CNA Lifestyle. The group cited concerns about stigma, career consequences and the time treatment can require. Its guidance does not change treatment funding, but describes pressures patients may face alongside the bill.

Private clinics face competition from outside Singapore as well. The Business Times cited research by Iseas-Yusof Ishak Institute senior fellow Lee Poh Onn indicating that IVF in Malaysia could cost substantially less. The newspaper also reported that the Ministry of Health does not track how many Singaporeans seek IVF abroad, so the scale of that cross-border demand is unclear.

Singapore’s falling birth rate forms the backdrop to the review: The Business Times reported a total fertility rate of 0.87 in 2025, down from 0.97 in 2024. Tan cautioned that fertility-treatment funding has limits as a response to that decline. “Singapore’s low TFR ultimately arises from social root causes, and initiatives through public health or technological solutions can only do so much,” she told the newspaper.